Rockville biotech OpGen faces delisting threat from Nasdaq

Rockville’s OpGen Inc. (NASDAQ: OPGN) has fallen out of compliance with the Nasdaq Stock Market after its share price failed to crack a buck over a 30-day period. The 20-year-old biotech said in filings with the Securities and Exchange Commission that it received a letter from the exchange June 5 about the need to maintain the minimum bid price of $1, per its listing rules. OpGen has 180 days to regain compliance.